The HERACLES trial was a multicenter open-label phase II trial that enrolled patients with wild-type KRAS exon 2, HER2 overexpressing metastatic colorectal cancer refractive to chemotherapy, and anti-EGFR therapy resistance. This evidence concerns the gene ERBB2 and metastatic colorectal cancer.